[Aplastic syndrome in myleran overdose].
D000305:Adrenal Cortex Hormones / Q000627:therapeutic use; D000741:Anemia, Aplastic / Q000139:chemically induced*; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D000925:Anticoagulants / Q000627:therapeutic use; D001803:Blood Transfusion; D002066:Busulfan / Q000008:administration & dosage / Q000009:adverse effects*; D003864:Depression, Chemical; D005260:Female; D006406:Hematoma / Q000139:chemically induced; D006410:Hematopoiesis / Q000187:drug effects; D006474:Hemorrhagic Disorders / Q000139:chemically induced* / Q000628:therapy; D006490:Hemostatics / Q000627:therapeutic use; D006801:Humans; D007945:Leukemia, Lymphoid / Q000188:drug therapy*; D007951:Leukemia, Myeloid / Q000188:drug therapy*; D008508:Medication Errors; D008875:Middle Aged; D013921:Thrombocytopenia / Q000139:chemically induced; D014815:Vitamins / Q000627:therapeutic use
D000305:Adrenal Cortex Hormones; D000900:Anti-Bacterial Agents; D000925:Anticoagulants; D006490:Hemostatics; D014815:Vitamins; D002066:Busulfan
Aplastische Syndrome bei Myleran -Uberdosierung.